|
Variable
|
All participants (n = 150)
|
NCI (n = 51)
|
MCI (n = 42)
|
Dementia (n = 57)
|
|---|
|
Demographic
|
|
Female, no. (%)
|
105 (70%)
|
40 (78%)
|
27 (64%)
|
38 (67%)
|
|
Age at death, years
|
88.7 ± 6.3
|
86.7 ± 6.7
|
88.1 ± 6.8
|
90.9 ± 4.7
|
|
Education, years
|
14.6 ± 2.9
|
13.9 ± 2.5
|
15.0 ± 2.8
|
15.0 ± 3.3
|
|
Race, no. W:AA
|
146:4
|
49:2
|
41:1
|
56:1
|
|
APOE ε4 carrier, no. (%)
|
33 (22%)
|
7 (14%)
|
11 (26%)
|
15 (26%)
|
|
PMI, hours
|
6.6 ± 3.8
|
6.2 ± 2.1
|
7.6 ± 5.6
|
6.2 ± 3.1
|
|
Cognitive function proximate to death
|
|
Global cognition score
|
−0.77 ± 1.01
|
0.10 ± 0.39
|
−0.47 ± 0.43
|
−1.80 ± 0.78
|
|
MMSE
|
21.9 ± 8.2
|
27.7 ± 1.9
|
24.9 ± 4.6
|
14.4 ± 8.1
|
|
Pathological
|
|
Macroinfarcts, no (%)b
|
45 (30%)
|
10 (20%)
|
15 (36%)
|
20 (35%)
|
|
Lewy bodies, no (%)b
|
25 (17%)
|
4 (8%)
|
1 (2%)
|
20 (35%)
|
|
Hippocampal sclerosis, no (%)b
|
14 (9%)
|
0 (0%)
|
4 (10%)
|
10 (18%)
|
|
Arteriolosclerosisb
|
1.39 ± 0.87
|
1.24 ± 0.84
|
1.38 ± 0.82
|
1.53 ± 0.93
|
|
Amyloid plaquesc
|
5.3 ± 5.9
|
2.9 ± 3.3
|
5.5 ± 6.5
|
7.3 ± 6.5
|
|
Tanglesc
|
1.1 ± 3.0
|
0.4 ± 1.7
|
1.1 ± 3.0
|
1.8 ± 3.7
|
-
Abbreviations: AA Afro-American, AD Alzheimer’s disease, MAP Memory and Aging Project, MCI mild cognitive impairment, MMSE mini mental state examination, NCI, no cognitive impairment, PMI postmortem interval, SD standard deviation, W White
-
aValues are mean ± SD unless noted otherwise
-
bGlobal values
-
cValues obtained in the contralateral dorsolateral prefrontal cortex (DLPFC) by immunohistochemistry with specific antibodies
